	US 12,226,436 B2
	Transplant material for treatment of heart disease
Daisuke Kajita, Suita (JP); Satsuki Fukushima, Suita (JP); Shigeru Miyagawa, Suita (JP); and Yoshiki Sawa, Suita (JP)
Assigned to ROHTO PHARMACEUTICAL CO., LTD., Osaka (JP)
Appl. No. 16/071,123
Filed by ROHTO PHARMACEUTICAL CO., LTD, Osaka (JP)
PCT Filed Jan. 18, 2017, PCT No. PCT/JP2017/001538 § 371(c)(1), (2) Date Jul. 19, 2018, PCT Pub. No. WO2017/126549, PCT Pub. Date Jul. 27, 2017.
Claims priority of application No. 2016-008096 (JP), filed on Jan. 19, 2016.
Prior Publication US 2021/0187031 A1, Jun. 24, 2021
Int. Cl. A61K 35/28 (2015.01); A61K 35/35 (2015.01); A61K 35/51 (2015.01); A61K 35/545 (2015.01)

CPC A61K 35/28 (2013.01) [A61K 35/35 (2013.01); A61K 35/51 (2013.01); A61K 35/545 (2013.01)]

2 Claims

1. A method for improving cardiac function, said method comprising:

treating isolated human adipose-derived regenerative cells with a PPARγ agonist,

contacting the treated human adipose-derived regenerative cells with an adhesive agent for 5 minutes to 10 minutes before transplantation to form a transplant material comprising a cell cluster, and

covering a cardiac surface of a subject in need thereof with said transplant material,

wherein said isolated human adipose-derived regenerative cells comprise mesenchymal stem cells and mesenchymal progenitor cells,

wherein said adhesive agent comprises fibrinogen and,

wherein said isolated human adipose-derived regenerative cells in said cell cluster are autologous with respect to said subject.